CRISPR Therapeutics AG — Director's Dealing 2021

Dec 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2021-12-03

Reporting Person: Kulkarni Samarth (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-03	Common Shares	M	80000	—	Acquired	299153	Direct
2021-12-06	Common Shares	F	37818	$69.17	Disposed	261335	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-03	Restricted Stock Units	$	M	80000	Acquired		Common Shares (80000)	Direct

Footnotes

F1: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022.

F2: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3: On December 3, 2019, the reporting person was granted 120,000 restricted stock units. On December 3, 2021, 80,000 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.